IL320332A - Methods for treating cancer - Google Patents

Methods for treating cancer

Info

Publication number
IL320332A
IL320332A IL320332A IL32033225A IL320332A IL 320332 A IL320332 A IL 320332A IL 320332 A IL320332 A IL 320332A IL 32033225 A IL32033225 A IL 32033225A IL 320332 A IL320332 A IL 320332A
Authority
IL
Israel
Prior art keywords
methods
treating cancer
cancer
treating
Prior art date
Application number
IL320332A
Other languages
Hebrew (he)
Original Assignee
Antares Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antares Therapeutics Inc filed Critical Antares Therapeutics Inc
Publication of IL320332A publication Critical patent/IL320332A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IL320332A 2022-10-21 2023-10-20 Methods for treating cancer IL320332A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263418089P 2022-10-21 2022-10-21
US202363443877P 2023-02-07 2023-02-07
US202363469252P 2023-05-26 2023-05-26
PCT/US2023/077441 WO2024086809A1 (en) 2022-10-21 2023-10-20 Methods for treating cancer

Publications (1)

Publication Number Publication Date
IL320332A true IL320332A (en) 2025-06-01

Family

ID=88874777

Family Applications (1)

Application Number Title Priority Date Filing Date
IL320332A IL320332A (en) 2022-10-21 2023-10-20 Methods for treating cancer

Country Status (10)

Country Link
EP (1) EP4605392A1 (en)
JP (1) JP2025538097A (en)
KR (1) KR20250110370A (en)
CN (1) CN120418247A (en)
AU (1) AU2023364551A1 (en)
CL (1) CL2025001163A1 (en)
IL (1) IL320332A (en)
MX (1) MX2025004532A (en)
TW (1) TW202421628A (en)
WO (1) WO2024086809A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202303419D0 (en) * 2023-03-08 2023-04-19 Otsuka Pharma Co Ltd Compounds
WO2025077778A1 (en) * 2023-10-12 2025-04-17 上海宇道生物技术有限公司 Carboxylic acid compound and preparation method therefor and use thereof
WO2025011684A2 (en) * 2023-10-20 2025-01-16 上海宇道生物技术有限公司 N-sulfonamide nitrogen-containing fused heterocyclic compound, and application thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018055316A1 (en) * 2016-09-26 2018-03-29 Centre National De La Recherche Scientifique Compounds for using in imaging and particularly for the diagnosis of neurodegenerative diseases
WO2022213975A1 (en) * 2021-04-08 2022-10-13 Jacobio Pharmaceuticals Co., Ltd. Compounds targeting y220c mutant of p53

Also Published As

Publication number Publication date
TW202421628A (en) 2024-06-01
AU2023364551A1 (en) 2025-05-08
WO2024086809A1 (en) 2024-04-25
CL2025001163A1 (en) 2025-10-03
KR20250110370A (en) 2025-07-18
MX2025004532A (en) 2025-07-01
CN120418247A (en) 2025-08-01
EP4605392A1 (en) 2025-08-27
JP2025538097A (en) 2025-11-26

Similar Documents

Publication Publication Date Title
IL304275A (en) Methods for treating cancer
IL312680A (en) Methods for treating cancer
IL287907A (en) Methods for treating cancer
IL320332A (en) Methods for treating cancer
PT4225297T (en) Combination therapy for treating cancer
ZA202310076B (en) Combination therapies for treating cancer
IL289811A (en) Method of treating cancer
IL319513A (en) Compounds for treating cancer
PL4048284T4 (en) Method for treating cancers
AU2024225706A1 (en) Methods for treating breast cancer
CA3262155A1 (en) Compounds for treating cancer
CA3254949A1 (en) Combination therapy for treating cancer
IL320471A (en) Methods for treating dll3-expressing cancer
IL305974A (en) Pharmaceutical combinations for treating cancer
IL317472A (en) Eravacycline for treating cancer
GB202412414D0 (en) Methods for treating cancer
GB201909466D0 (en) Compounds for treating cancer
HK40109687A (en) Methods for treating cancer
GB202300668D0 (en) Cancer treating compounds
HK40095092A (en) Methods for treating cancer
IL317573A (en) Combination therapy for treating cancer
IL316016A (en) Combination therapy for treating cancer
IL316019A (en) Combination therapy for treating cancer
GB201910244D0 (en) Method for treating cancer
CA3252465A1 (en) Cancer treatment